Insilico Medicine, a Baltimore-based leader in artificial intelligence for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited.
from Dementia Big http://ift.tt/2v5fh9M via alcoholic dementia
http://ift.tt/2eUJuma
No comments:
Post a Comment